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Abstract
The European Society of Paediatric Radiology (ESPR) research committee was established to initiate, drive forward and foster
excellence in paediatric imaging, paediatric image-guided intervention and radiation protection research, by facilitating more
evidence-based standards, protocols and multi-institutional collaborations. The ESPR Strategic Research Agenda outlines our
current research approach, highlighting several areas of paediatric imaging where the society can help guide current and future
research, and emphasizing those areas where early research (“seed”) funding may need to be allocated by this and other societies
as precursors to larger grant applications. The key aims are to evaluate normal variation in order to be able to confidently diagnose
disease states, develop robust image-based classification systems to aid diagnosis and treatment monitoring, and help develop
evidence-based clinical guidelines using current literature and experience to identify knowledge gaps. For this reason, the
development of evidence-based imaging pipelines, broken down step-by-step to include diagnosis, classification and clinical
effectiveness, should be the end goal for each disease entity for each affected child. Here, we outline the 2019 ESPR Strategic
ResearchAgenda along three points in the clinical imaging pipeline: clinical referral, disease diagnosis and evolution, and clinical
therapeutic evaluation and effectiveness. Through multicentre trials, using existing high-level experience and expertise, and
nurturing the next generation of researchers, we will be able to achieve these aims.
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Introduction
Paediatric radiology is the skill of accurate and appropriate
imaging of childhood disease, a key component being safety
[1, 2]. The European Society of Paediatric Radiology (ESPR)
strives that all children should be examined and diagnosed by
specialists with appropriate expertise, using the best possible
technology available. Ideally, therefore, there should be
round-the-clock paediatric radiology expertise available either
on-site or via a clinical network of specialists.
Whilst several countries have dedicated large children’s
hospitals with specialist radiology staff with paediatric skills,
* Owen J. Arthurs
owen.arthurs@gosh.nhs.uk
1 Department of Radiology,
Great Ormond Street Hospital,
London, UK
2 NIHR UCL Great Ormond Street Institute of Child Health
Biomedical Research Centre,
London, UK
3 Department of Radiology,
Emma Children’s Hospital – Amsterdam UMC,
University of Amsterdam,
Amsterdam, The Netherlands
4 Service of Radiology,
IRCCS Istituto Giannina Gaslini,
Genoa, Italy
5 Department of Paediatric Neurology,
Hospital of Goethe University,
Frankfurt am Main, Germany
6 Department of Paediatric Radiology,
University Leipzig,
Leipzig, Germany
7 Department of Radiology,
Haukeland University Hospital,
5020 Bergen, Norway
8 Department of Clinical Medicine,
University of Bergen,
Bergen, Norway
Pediatric Radiology (2019) 49:983–989
https://doi.org/10.1007/s00247-019-04406-4
The Author(s) 2019
much of paediatric imaging is undertaken by nonspecialists.
The most recent publication from the Royal College of
Radiologists in the United Kingdom estimates that 75% of
children’s radiographs and scans are taken in smaller, nonspe-
cialist hospitals [3], by radiographers who have no specific
training in imaging children, and interpreted by radiologists
with less than 6 months’ specialist training. Although the tech-
nology for transferring images is now widely available, the
majority of centres (62% in the United Kingdom, 90% in
Norway, for example) still do not have access to a 24-h
paediatric opinion [4, 5]. Across Europe, many paediatric ex-
aminations are therefore reported by general radiologists, or
non-radiology clinicians.
The importance of this child-centric and child-specific ap-
proach has been addressed in several recent publications
showing a significant rate of major disagreements between
interpretations of paediatric imaging studies by general radi-
ologists and those of specialty radiologists at a tertiary care
paediatric hospital [5, 6]. Notably, there was a significant cor-
relation between the second opinion interpretations and the
final diagnoses, thus assuming a crucial role in patient man-
agement. These findings are similar to studies on specialist
reporting in different adult populations and underline the im-
portance of subspecialty training [7–12]. The results are
alarming and should fuel our efforts to enhance education
and research within paediatric imaging.
By strengthening research in paediatric radiology, we
will increase the impact of our subspecialty and form a
research basis for the foundation for paediatric radiology
clinical practice. With this in mind, the ESPR research
committee was established to initiate, advance and foster
excellence in paediatric imaging, including paediatric
image-guided intervention and radiation protection re-
search. It would do this by facilitating the progression
away from individual, locally isolated projects toward
more evidence-based standards, protocols and multi-
institutional collaborations, which could be used on both
a national and international basis.
The ESPR research committee has identified several areas
of paediatric imaging for essential research, but until now has
not had a formal Strategic Research Agenda under which to
coordinate these projects. This document acts not only as a
strategic agenda for the society to help guide current and fu-
ture research, ensuring that it aligns closely with wider
European Society of Radiology (ESR)’s European Institute
for Biomedical Imaging Research and European commission
funding calls, but also to highlight those particular areas where
early research (“seed”) funding may need to be allocated by
this and other societies as precursors to larger grant applica-
tions. Through multicentre trials, existing high-level expe-
rience and expertise, and nurturing the next generation of
researchers, we will be able to achieve these aims. This
research agenda is mission orientated and impact focused,
and necessitates the free movement of data among
researchers. In order to achieve our aim, the ESPR re-
search committee underwrites the policy in which re-
search data are Findable, Accessible, Interoperable, and
Reusable (FAIR) [13].
Research that can clearly measure or emphasize the advan-
tages of specialized imaging is the future of our specialty.
Investment in well-designed research trials to address today’s
challenges and questions will improve the health care of to-
morrow’s children. Clearly, all resources are finite, so time and
funding should be prioritized to the most urgent and far-
ranging problems. Areas of current study that warrant further
work include non-oncological bowel imaging in children,
management of radiation exposure in paediatric imaging and
the application of advanced new imaging methods to complex
paediatric disease.
The key aims of the ESPR research committee are to:
1. Improve imaging-based paediatric research through
multicentre trials and collaborative working, including
data sharing;
2. Document normal variation in imaging findings to be able
to confidently differentiate disease from normal;
3. Develop robust image-based classification systems to aid
diagnosis and treatment monitoring, and
4. Help develop evidence-based clinical guidelines using
current literature and experience to identify knowledge
gaps.
Overarching strategy
Evidence-based clinical imaging pathways are the ultimate
end point of successful imaging research as they provide an
efficient system of the maximum and minimum imaging re-
quirements to make a diagnosis in a particular clinical situa-
tion, using the best available literature at the time. If imple-
mented correctly, they also allow for a reduction in practice
variation leading to overall improvement in clinical care. For
this reason, the development of evidence-based imaging pipe-
lines, broken down step-by-step to include diagnosis, classifi-
cation and interval monitoring, should be the end goal for each
disease entity for each child.
The three steps in any imaging pipeline, loosely based on
Fryback and Thornbury framework [14], are (Fig. 1):
& Clinical referral and diagnostic criteria: risk factors and
clinical presentation.
& Disease diagnosis and evolution: image acquisition and
analysis.
& Clinical impact: therapeutic evaluation and clinical
effectiveness.
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Clinical referral and diagnostic criteria
The appropriate imaging for the correct clinical scenario is still
led by experience rather than evidence. In many cases, imag-
ing algorithms have developed through patient and clinician
experience and expertise without being validated through
comprehensive studies. Clinical imaging referral guidelines
play a fundamental role in enhancing appropriateness and thus
the implementation of the principle of justification. Modern
systematic reviews and meta-analyses provide a critical re-
view of the existing literature and can provide much needed
insight, but expert opinion is often the resource used when
evidence is lacking. Literature studies or questionnaires also
help to highlight current knowledge and practice gaps, and can
initiate new research projects.
The ESPR recognizes the value of expert opinion by
supporting several imaging task forces that have been active
in evaluating the literature within their areas of expertise and
generating consensus documentation. Here, the ESPR abdom-
inal (gastrointestinal and genitourinary) task force can serve as
an excellent example. Over the past 10 years, in close collab-
oration with other international societies such as the European
Society of Uroradiology, the task force has provided imaging
recommendations that can be implemented in daily practice
[15, 16]. These task force recommendations are preferentially
published in the society journal Pediatric Radiology. Several
of these have become implemented as paediatric imaging re-
ferral guidelines in the recent ESR iGuide clinical decision
support system for referrers and radiologists [17].
Disease diagnosis and evolution
Image acquisition
One of the fundamental aspects of paediatric imaging research
is the ability to be able to share data sets among centres,
particularly in cases of rare disease. However, the inability
to standardize image acquisition (operating protocols and spe-
cific sequence acquisitions) hampers the ability to analyse
comparable data across institutions, occasionally resulting in
additional imaging tests being performed. It is for this reason
that the standardization of technical parameters is paramount
going forwards, but also perhaps the largest hurdle to over-
come. This challenge occurs on many levels, includes the
standardization of imaging approaches (e.g., the use of ultra-
sound [US] in cystic kidney disease [18]), imaging protocols
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Fig. 1 European Society of Paediatric Radiology 2019 Strategic
Research Agenda: Improving imaging for tomorrow’s children. The
diagram outlines the pipeline from clinical referral to disease diagnosis
to disease evolution. Disease diagnosis is underpinned by the two pillars
of image acquisition (technical performance) and image analysis
(diagnostic performance). Ultimately, only clinically impactful and
effective imaging should be employed
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(e.g., the use of gadolinium for joint disease activity assess-
ment in juvenile idiopathic arthritis [19]), and further specific
sequences within imaging protocols (e.g., the use of diffusion-
weighted imaging in oncology assessment as routine [20]).
Paediatric oncology and musculoskeletal imaging are good
examples of how this has been achieved through international
guidelines, but this is lacking in several other areas. For ex-
ample, the combined efforts of the OMERACT (Outcome
Measures in Rheumatology) and Health e-Child have devel-
oped working guidelines for imaging of the wrist and knee in
juvenile idiopathic arthritis [21–23]. Within the European
Paediatric soft-tissue sarcoma study group, there has been
strong involvement of paediatric radiologists and nuclear phy-
sicians with respect to the European Frontline and Relapsed-
RhabdoMyoSarcoma Study (FaR-RMS). Minimum clinical
imaging protocols have been proposed and accepted, and par-
ticipating centres will use the Quality and Excellence in
Radiotherapy and Imaging for Children and Adolescents with
Cancer across Europe in Clinical Trials (QUARTET) network
to share imaging. This allows for both expert reading and
multicentre-multinational research. Similar initiatives have
been established across a range of children’s cancers, such
as the Society for Pediatric Oncology brain tumour imaging
group, encouraging the translation of new imaging methods
into clinical trials to assess their effectiveness.
Decisions regarding which imaging modality is best to an-
swer which clinical question often involve trade-offs between
ease of access to imaging types, radiation dose and the level of
detail required. This is all the more difficult when studies are
not only multicentre but also multinational, as there is unequal
access to more advanced imaging techniques (e.g., high field
magnetic resonance imaging [MRI] or positron emission to-
mography) between centres and countries. Meanwhile, reduc-
ing the radiation dose of ionizing radiation modalities (radi-
ography, fluoroscopy, computed tomography, nuclear medi-
cine) remains a priority, while maintaining or improving im-
age quality [24]. Improving the quality and efficiency of mo-
dalities that do not use ionizing radiation (US, MRI), for ex-
ample improving MRI to make it faster, more capable and
potentially avoiding sedation or anaesthesia, is clearly a prior-
ity [2, 25]. Image acquisition strategies in children must eval-
uate dose in twoways: by improving dose efficiency in studies
in which ionizing radiation cannot be avoided, but also by
improving non-radiation-based imaging techniques.
Good examples of the significant work done across Europe
in this regard include the ESPR’s pivotal role in the PiDRL
project (European Diagnostic Reference Levels for Pediatric
Imaging; http://www.eurosafeimaging.org/pidrl). This multi-
partner European Consortium-lead project headed by the ESR
was intended to provide European Diagnostic Reference Levels
(DRLs) for paediatric examinations. By doing so, their use
would be promoted to advance the optimization of radiation
protection of paediatric patients, with a focus on CT,
interventional procedures using fluoroscopy, and digital radio-
graphic imaging. Their first steps were to agree on a methodol-
ogy for establishing and using dose reference levels for paedi-
atric imaging, and to update and extend the European DRLs to
cover more procedures and a wider patient age/weight range.
The final document including European guidelines on dose
reference levels for paediatric imaging has been endorsed and
published by the European Commission and is available in the
Radiation Protection Series [26].
However, more work is needed. The International
Commission on Radiological Protection (ICRP) advises that
clinical indication-specific, rather than examination-specific,
dose reference levels are desirable. For example, CT exami-
nations of the same anatomical regions can be performed with
different techniques, and consequently different dose expo-
sures, depending on the clinical indication. However, there is
very limited information about clinical-indication specific
dose reference levels for medical imaging in children. The
next project to establish new European clinical dose reference
levels in children is long awaited.
Image analysis
Once image acquisition standardisation is achieved, simulta-
neously there must be image analysis standardisation, i.e. of
classifications, measurements and scoring systems. Key prior-
ities for image analysis (or assessment of diagnostic perfor-
mance) are to develop robust methods of diagnosing a specific
disease state, developing normal standards that stand up to
rigorous testing, validation and repeatability assessment, and
classification or scoring criteria with validation.
Normal reference appearances and values are essential to
correctly interpret diagnostic images, particularly in children
as normal appearances change during growth. The ability to
distinguish normal variations from abnormal disease in its
earliest form is the cornerstone of paediatric imaging, but this
is largely experiential rather than evidential in its current prac-
tice, leading to wide variations in interpretation without evi-
dence to the contrary. All trainee radiologists will be familiar
with Keats’ standard textbook of normal variants whichmimic
disease, but the “evidence” behind this book is experiential
[27]. Normal standards are frequently compiled into an atlas,
against which specific imaging phenotypes can be assessed.
Some reference standards are becoming available for normal
variations in specific clinical scenarios, for example the refer-
ence standards for kidney size [28, 29]. There are no normal
standards for whole-body MRI, which poses particular prob-
lems for diagnosing abnormalities [30]. In other areas of mus-
culoskeletal imaging, recent advances have beenmade regard-
ing image-based classification systems for juvenile dermato-
myositis [31] and establishment of normal US-based refer-
ences for the wrist [32].
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Areas for future study would include wide variation of
ventricular size in healthy newborns and young children,
which is crucial knowledge to identify hydrocephalus [33],
or the evaluation of normal bowel wall thickness to evaluate
inflammatory bowel disease. Collaborative cohort studies in-
cluding paediatric radiologists are clearly needed: for exam-
ple, a prospective cohort study from fetal life until young
adulthood in a multiethnic urban population based in
Rotterdam (known as the Dutch Generation R study) that is
using long-term imaging as part of assessments (https://www.
generationr.nl/researchers/data-collection/).
Clinical impact: Therapeutic evaluation and clinical
effectiveness
Many of the aspects of image acquisition and analysis apply
equally, whether it is the first or last scan in a series of complex
patient interactions. But there are more questions than answers
to be explored here: When to image? What is the appropriate
time interval to image in certain diseases?What are the risks in
doing so (missing early disease states or relapse) versus those
of imaging too early (latency bias)? Imaging is frequently
used to evaluate disease evolution despite a lack of evidence
for its clinical utility. Accurate imaging markers of effective
therapy are essential for disease reassessment to be worth-
while. Imaging is frequently used in an attempt to evaluate a
patient’s response to therapy, whether pharmacological or sur-
gical. Whilst it is relatively straightforward to image and ob-
serve change associated with treatment, proving that a change
has occurred outside of normal variation and that it is causally
linked to the treatment is not always clear. Clinical improve-
ment may not correspond to imaging changes, and vice versa,
or may be temporally displaced. Worse still, imaging may
identify incidental lesions with the risk of overtreatment.
How accurately we can predict disease monitoring is challeng-
ing, and imaging frequency may need to be tailored to indi-
vidual disease states and risk factors.
Imaging is heavily used in paediatric oncology assessment
and reassessment, and has already demonstrated problem
areas. For example, imaging following tumour resection can
be challenging: Marginal amounts of residual tumours may
not be visible using current imaging techniques, postsurgical
contrast enhancement around resection margins can be phys-
iological or reactive and they do not necessarily infer residual
tumour. Reduction of tumour volume of >50% following
treatment may be termed “partial response,” but the exact
nature of the residual tissue is currently not determinable.
Within the European paediatric soft-tissue sarcoma group,
several recent retrospective studies have evaluated the impact
of imaging findings on patient care, using rhabdomyosarcoma
patients as the example group. One study showed that early
radiologic response to chemotherapy (volumetric tumour re-
duction) did not infer a survival advantage in patients with
rhabdomyosarcoma [34]. Another study showed that indeter-
minate lung nodules should be treated as non-metastatic in
otherwise non-metastatic patients in rhabdomyosarcoma [35]
and other studies have sought to evaluate the role of follow-up
imaging [36–38]. Through evaluating the evidence for widely
held beliefs, good collaborative paediatric radiologic research
can clearly have a major clinical impact on treatment protocols
and patient care.
Examples of successful research along
imaging pipelines
One example of a current and ongoing specific disease pipe-
line is the current pan-European research initiative into juve-
nile idiopathic arthritis (JIA). The Euro-Im-JIA, launched in
2013–14, addresses the current lack of imaging markers for
JIA through developing precise, validated child-specific im-
aging biomarkers and scoring systems to allow for evidence-
based clinical practice as well as for robust drug trials. The
entire project is founded on multidisciplinary collaboration
across several well-established research groups across
Europe, including paediatric rheumatologists, radiologists,
dentists and oral surgeons as well as medical physicists and
mathematicians. This project proposes a standardisation of the
assessment of active and permanent change in JIA, allowing
better assessment of disease evolution and therapeutics [21,
23]. If successful, this work will allow earlier, more robust
diagnosis, a more sensitive classification of potential for the
development of pathology, and thus the opportunity for earlier
intervention to reduce chronic change and disability. JIA is, of
course, only one example of several childhood illnesses with
lifelong consequences. Several other rheumatological condi-
tions and hip problems (such as developmental hip dysplasia,
slipped capital femoral epiphysis and femoral acetabular im-
pingement) can all affect joints in childhood and adolescence,
which may lead to accelerated degenerative disease in adult-
hood and the eventual need for hip replacement, often at a
relatively young adult age. Imaging plays a key role in diag-
nosing these conditions, monitoring their progression and
evaluating for complications, and thereby guiding therapy.
Cancer imaging is another such pipeline likely to improve
in several domains for children’s services in the near future.
Hybrid imaging is improving sensitivity across different im-
aging modalities, and may simultaneously improve specifici-
ty, particularly for metastatic disease [39, 40]. Newer cell-
based imaging markers will become important in the future,
not only to differentiate tumour subtypes at diagnosis, but also
to target therapy and measure tumour responses. However,
most cancer trials involving imaging are designed with imag-
ing as an adjunct, or addition, to the main trial regarding new
treatment paradigms or responses. This is true of many non-
cancer imaging trials, which tend not to be led by paediatric
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radiologists but other specialists, such as oncologists or cardi-
ologists. The ESPR is keen to foster imager-led research trials
to improve the delivery of high-quality imaging, as well as to
have radiologists play their part in larger clinical trials.
Coordinated networks
Some of the data needed to be able to address these vital
questions are already acquired and currently sit on disparate
hospital networks across different countries and institutions.
There are several issues with data access and coordinated
studies, but multiuser sharing platforms such as those provid-
ed by the European Initiative in Biomedical Imaging
Research, the QUARTET network, and the Dutch Health
Research Infrastructure (Health RI (https://www.bbmri.nl/
health-ri/) may help coordinate these studies in the future.
The idea of a single imaging repository with anonymised
access to vast amounts of verified clinical data is a long way
from being possible with current technology and border
controls, including industry, consent and ethical issues.
In the meantime, smaller national networks have developed
successful collaborations with free data sharing within a strict
research agreement and geographical distribution. There are
many reference disease centres now established in different
countries, providing care within and between nations. One
function is to act as the liaison for imaging and clinical data
access for European level projects, provided patients have
consented for their data to be used in ethically approved mul-
tinational projects, with the necessary safeguards.
Rare diseases
One of the most challenging and frustrating aspects of paediat-
ric disease are rare diseases because research efforts are ham-
pered by small numbers at each institution and often limited
funding. Improved data transfer technology now allows better
sharing of information across institutions, and universal patient
medical records offer opportunities for improved collaboration
on rare diseases, which will encourage more collaborative re-
search efforts. However, as has already been described in
standardisation, one obstacle to collaboration is heterogeneity
in performing and reporting paediatric imaging. By agreeing to
a set of standard methods on how to perform a certain test, the
results will be easier to compare across different institutions,
which will ultimately improve patient care.
Conclusion
Imaging is paramount for efficient, high-quality paediatric med-
icine. Clinical and research pipelines to evaluate rare diseases
will necessarily involve multiple aspects of this strategy, includ-
ing establishing imaging protocols on the best diagnostic ap-
proaches, normal standards for phenotyping, imaging-based
scoring systems to evaluate disease severity, clinical correlation
with genetic and other biomarkers, and finally evaluation of po-
tential treatments against these scoring systems and biomarkers.
Several of these initiatives (particularly dose reduction and
optimisation, data registries and improving image analysis)
are shared with other paediatric imaging representatives, such
as the Paediatric Imaging Research Committee of the
American College of Radiology (White paper [41]) and we
look forward to joint initiatives.
Fostering clinical research collaboration at an international
level is the ESPR research committee’s goal over the next
5 years to facilitate improvements in paediatric health care.
Disease prevention and other aspects of health care have not
been neglected nor will support for other initiatives be aban-
doned. These are simply the areas that we collectively believe
as a society require the most intellectual and financial input in
the next 5 years in order to develop imaging markers of disease
that can be relied upon for diagnosis, monitoring and therapeu-
tic evaluation. Fundamentally, we are investing in these priori-
ties as the ESPR’s strategic agenda for 2019–2022. We look
forward to the progress that will be made on these and other
areas and to updating this research strategy in 3–5 years.
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